Q-omics provides the consensus-scored RPS3AP35 profile across patient tissues and cancer cell-line models. RPS3AP35 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, RPS3AP35 is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, RPS3AP35 RNA expression shows 7,448 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight THCA, BRCA, and ESCA as cancer lineages where RPS3AP35 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS3AP35 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS3AP35 survival associations across molecular data types. RPS3AP35 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS3AP35 RNA expression–survival associations across cancer types. High RPS3AP35 expression shows unfavorable associations in THCA, COAD, UCS and STAD, but favorable associations in LGG and GBM. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for RPS3AP35 RNA expression.
This table summarizes RPS3AP35 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPS3AP35. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS3AP35 shows lower tumor expression in BRCA. The BRCA box plot shows higher RPS3AP35 RNA expression in normal versus tumor tissue (log2 FC = −0.038, t-test p = .028).
This table shows molecular features associated with RPS3AP35 in patient tissues and cancer cell lines. In patient samples, RPS3AP35 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
